ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,555.74
-0.16%
US Tech 100
19,107.20
-1.02%
Dow Jones
40,358.09
-0.16%
Brent Oil
80.605
-0.21%
Bitcoin
65,931.36
0.01%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Calliditas Therapeutics AB (CALT)

  7. Calliditas Therapeutics AB (CALT) News

Calliditas Therapeutics AB

Calliditas Therapeutics AB (CALT)

Caltagirone SPA
38.50
-0.20
(-0.52%)
Closed July 23 4:00PM
Delayed by 15 minutes
38.50
0.00
(0.00%)
After Hours: 4:00PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

CALT News

Official News Only

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
May 30 2024
CALT (-0.52%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
May 28 2024
CALT (-0.52%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
May 23 2024
CALT (-0.52%)

CALT Discussion

View Posts
tw0122 tw0122 2 months ago
$CALT $38 STOCKHOLM, May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) as well as a real-world analysis of the use of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN). These were presented at ERA 2024 virtually and in Stockholm on May 23 - 26, 2024.

The presented efficacy analysis of Nefecon and sparsentan showed that treatment with Nefecon for 9 months was associated with estimated glomerular filtration rate (eGFR) benefit compared with continuous treatment with sparsentan.

Additionally, the findings of a real-world analysis of challenges associated with the use of systemic glucocorticoids demonstrate significant side effects and costs for IgAN patients treated with systemic glucocorticoids (SGC), such as Prednisone and Prednisolone.

"It was wonderful to participate in ERA 2024 and present data contributing to the discussion on the need for effective treatments in IgAN," said Richard Philipson, Chief Medical Officer of Calliditas, " We continue to gather evidence that highlights the importance of treating the underlying autoimmune pathogenesis associated with IgAN, and we believe TARPEYO, as the only approved immunomodulating therapy designed to target the production of Gd-IgA1, has the potential to become a cornerstone therapy in IgAN."

Poster presentation details are below and will be available on the Presentations and Publications page on the Calliditas' corporate website following the meeting.

Presentation Analyses:

Title: "Matching-adjusted indirect comparison of eGFR in patients with immunoglobulin A nephropathy treated with Nefecon (TRF budesonide) or sparsentan"

A matching-adjusted indirect comparison (MAIC) methodology is a widely accepted and relevant methodology for comparing treatments across trials in the absence of head-to-head comparisons. Here the effects of Nefecon, marketed as TARPEYO® and sparsentan, marketed as FILSPARI™, on kidney function deterioration in patients with IgAN were compared, as assessed by eGFR change from baseline at 9, 12 and 24 months. Results from the MAIC showed significantly favorable effects of Nefecon versus sparsentan on eGFR across all time points analyzed. Mean differences in the absolute change in eGFR of 5.68mL/min/1.73 m2 (95% credible interval [Crl] 3.14, 8.20; p
👍️0
Monksdream Monksdream 4 months ago
CALT over $20
👍️0

Your Recent History

NASDAQ
CALT
Calliditas Therapeutics AB
LSE
IMI
Imi
BIT
F12084
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved